tradmap

PBH Financials Prestige Consumer Healthcare Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 2.9% per year over the past 5 years.
  • Net income has grown in line with revenue (2.9% vs 2.9% per year).
  • Operating margin has contracted, at 28.4% in the latest year.
  • Free cash flow has grown 2.9% per year over the past 5 years.

Financial health

  • Total debt ($994M) exceeds cash ($64M); net debt is $930M.
  • Total debt has grown slower than revenue (-7.6% vs 2.9% per year).
  • Total debt is 2.9× EBITDA.
Revenue & net income
-$82M $528M $1B $0 2012 2014 2016 2018 2020 2022 2024 2026
RevenueNet income
Margins (gross / operating / net)
-7% 25% 58% 0% 2012 2014 2016 2018 2020 2022 2024 2026
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-6% 12% 29% 0% 2012 2014 2016 2018 2020 2022 2024 2026
ROEROA
Free cash flow (CFO − capex)
$0 $125M $250M 2012 2014 2016 2018 2020 2022 2024 2026
Free cash flow
Cash vs total debt
$0 $1B $2B 2012 2014 2016 2018 2020 2022 2024 2026
CashTotal debt
Cash flow: operating / investing / financing
-$805M -$81M $643M $0 2012 2014 2016 2018 2020 2022 2024 2026
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2026 $1.1B $190M 54.7% 28.4% 10.1% 5.4% $246M $994M $64M
2025 $1.1B $215M 55.8% 29.6% 11.7% 6.3% $243M $992M $98M
2024 $1.1B $209M 55.5% 30.4% 12.6% 6.3% $239M $1.1B $46M
2023 $1.1B -$82M 55.4% -2.0% -5.7% -2.5% $222M $1.3B $58M
2022 $1.1B $205M 57.1% 30.4% 13.0% 5.6% $250M $1.5B $27M
2021 $943M $165M 58.0% 31.5% 12.1% 4.8% $213M $1.5B $32M
2020 $963M $142M 57.3% 30.2% 12.2% 4.0% $203M $1.7B $95M
2019 $976M -$36M 56.9% 6.9% -3.3% -1.0% $179M $1.8B $28M
2018 $1.0B $340M 55.4% 20.7% 28.8% 9.0% $198M $2.0B $33M
2017 $882M $69M 56.7% 23.3% 8.4% 1.8% $146M $2.2B $42M
2016 — $100M — — 13.4% 3.4% $173M $1.6B $27M
2015 — $78M — — 12.5% 3.0% $150M $1.6B $21M
2014 — $73M — — 12.9% 4.0% $109M $934M $28M
2013 — $66M — — 13.7% 3.8% $127M $971M $16M
2012 — $37M — — 9.2% 2.1% $67M $1.1B $19M

Valuation over time

How the market has priced PBH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 9.6 19.2 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 1.8 3.6 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S

Frequently asked questions

Is PBH growing its revenue and profit?

Over the past 5 years, Prestige Consumer Healthcare Inc.'s revenue has grown 2.9% per year, and net income grown 2.9% per year. These are computed facts, not advice.

How much debt does PBH have?

As of FY2026, Prestige Consumer Healthcare Inc. reported $994M of total debt against $64M of cash.

What is PBH's profit margin?

In FY2026, gross margin was 54.7%, operating margin 28.4%, and net margin 17.5%.

What is PBH's P/E ratio?

Prestige Consumer Healthcare Inc.'s P/E (TTM) is 13.70 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the PBH stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 12.4× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.